Evolving immunotherapeutic strategies in bladder and renal cancer.
作者信息
Griffiths T R L, Mellon J K
机构信息
Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester General Hospital, Leicester, UK.
出版信息
Postgrad Med J. 2004 Jun;80(944):320-7. doi: 10.1136/pgmj.2003.013508.
Abstract
For patients with urological cancers, immunotherapy is currently a treatment option for metastatic renal cell carcinoma, and those with "high risk" superficial bladder cancers. In this review, our current understanding of tumour immune escape is discussed. The principles and role of current immunotherapies for these tumours are described, and new areas of immunotherapeutic promise are highlighted.
摘要
相似文献
1
Evolving immunotherapeutic strategies in bladder and renal cancer.
Postgrad Med J. 2004 Jun;80(944):320-7. doi: 10.1136/pgmj.2003.013508.
2
The role of immunotherapy for urological tumours.
Br J Urol. 1997 Mar;79(3):307-16. doi: 10.1046/j.1464-410x.1997.00301.x.
3
[BCG immunotherapy in the treatment of superficial bladder tumors].
Orv Hetil. 1986 Oct 5;127(40):2441-6.
4
[Immunotherapy in superficial bladder carcinoma].
Arch Esp Urol. 2000 Dec;53(10):879-92.
5
Conservative treatment of high grade superficial bladder tumours.
Arch Ital Urol Androl. 2005 Dec;77(4):215-8.
6
[Update on the medical treatment of urologic tumors].
Bull Cancer. 2000 Jan;87(1):71-5.
7
[Nonspecific immunotherapy with BCG vaccine in bladder tumors].
Khirurgiia (Sofiia). 1990;43(1):48-53.
8
New approaches to intravesical chemo-immunotherapy in superficial bladder cancer.
Prog Clin Biol Res. 1992;378:95-101.
9
Immunotherapy in genitourinary neoplasia.
J Urol. 1985 Jan;133(1):1-5. doi: 10.1016/s0022-5347(17)48760-x.
10
Advances in the treatment of superficial bladder cancer: optimizing BCG immunotherapy. Introduction.
Eur Urol. 1995;27 Suppl 1:1.
引用本文的文献
1
Shared occupational risks for transitional cell cancer of the bladder and renal pelvis among men and women in Sweden.
Am J Ind Med. 2008 Feb;51(2):83-99. doi: 10.1002/ajim.20522.
本文引用的文献
1
Defining bacillus Calmette-Guerin refractory superficial bladder tumors.
J Urol. 2003 May;169(5):1706-8. doi: 10.1097/01.ju.0000062605.92268.c6.
2
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.
J Urol. 2002 Nov;168(5):1964-70. doi: 10.1016/S0022-5347(05)64273-5.
3
Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.
J Urol. 2002 Jun;167(6):2408-12.
4
Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer.
BJU Int. 2002 May;89(7):671-80. doi: 10.1046/j.1464-410x.2002.02722.x.
5
The danger model: a renewed sense of self.
Science. 2002 Apr 12;296(5566):301-5. doi: 10.1126/science.1071059.
6
Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma.
Br J Cancer. 2002 Mar 4;86(5):768-73. doi: 10.1038/sj.bjc.6600152.
7
Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
N Engl J Med. 2001 Dec 6;345(23):1711-2. doi: 10.1056/NEJM200112063452317.
8
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
N Engl J Med. 2001 Dec 6;345(23):1655-9. doi: 10.1056/NEJMoa003013.
9
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
Br J Cancer. 2001 Oct 19;85(8):1130-6. doi: 10.1054/bjoc.2001.2076.
Zotero 插件